BenzingaAugust 7, 2026 at 9:14 AM NY28 days ago

Guggenheim Maintains Buy on Avalo Therapeutics, Lowers Price Target to $48

Guggenheim analyst Yatin Suneja maintains Avalo Therapeutics (NASDAQ:AVTX) with a Buy and lowers the price target from $50 to $48.

Read the Full Story at the Source

The summary here comes from the news provider; the rest of the article lives on the publisher's site — Benzinga

Companies in This Story